Eficácia da prednisolona associada à cefoperazona no tratamento intramamário de casos naturais de mastite clínica em vacas leiteiras
Carregando...
Data
2020-12-23
Autores
Franco, Ananda Finco Raposo
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
O objetivo deste estudo foi avaliar a eficácia da associação entre cefoperazona e prednisolona no tratamento de casos naturais de mastite clínica (MC) em bovinos leiteiros durante a lactação. Animais de 14 rebanhos comerciais foram distribuídos aleatoriamente em dois grupos experimentais, denominados como: 1) grupo PCEF: receberam tratamento intramamário contendo 250 mg de cefoperazona e 4 mg de prednisolona a cada 48h, totalizando 2 aplicações (N=147) e 2) grupo CEF: tratados somente com cefoperazona, conforme tratamento do grupo PCEF (N=141). Foram coletadas amostras de leite para cada quarto mamário incluído no estudo no dia da detecção do caso (D0), e 14 (D14) e 21 (D21) dias após D0, para realização de diagnóstico microbiológico e contagem de células somáticas (CCS). Os desfechos estudados foram cura microbiológica, cura clínica, recorrência de MC, risco de novas IMI em D14 e D21, CCS em D14 e D21 e produção de leite e CCS no 1o, 2o e 3o exames mensais após MC. Um total de 288 casos de MC foram randomizados em PCEF (n = 147) ou CEF (n = 141). A cura clínica (PCEF = 81,63% e CEF = 82,27%) e o tempo mediano (1o - 3o quartil) até a cura clínica [PCEF = 3,0 (2,5-4,0 dias) e CEF = 3,50 (3,0-4,0) dias] não foram diferentes entre os tratamentos. O risco de cura clínica foi 1,86 (IC 95%: 1,38-2,51) vezes maior para os casos leves, em relação aos moderados. A cura microbiológica (PCEF = 68,87% e CEF = 54,21%) não diferiu entre os tratamentos. Os casos associados a patógenos Gram-negativos foram 5,40 (IC 95%: 1,84-15,91) vezes mais propensos a serem curados do que aqueles associados a patógenos Gram-positivos. A recorrência de MC (PCEF = 26,67% e CEF = 21,93%) e o tempo mediano até a recorrência (PCEF = 63,5 e CEF = 65 dias) não diferiram entre os tratamentos. Para os casos com cultura negativa em D0, a incidência de nova IMI em D14 (PCEF = 18,75% e CEF = 34,78%) e D21 (PCEF = 28,13% e CEF = 39,13%) não foi diferente entre os tratamentos. A CCS foi numericamente maior em CEF do que em PCEF em D14 e D21, embora as diferenças não tenham sido estatisticamente xi significantes. Da mesma forma, não foram encontradas diferenças significantes entre a CCS ou a produção de leite no 1o, 2o e 3o teste mensal após o caso de MC. Os resultados deste estudo indicam que o tratamento intramamário de casos naturais de MC com PCEF não foi superior ao tratamento com CEF, com base no risco de cura clínica e microbiológica, recorrência de MC, risco de nova IMI, produção de leite e CCS.
The objective of this study was to evaluate the efficacy of a combination of cefoperazone and prednisolone for treatment of natural cases of clinical mastitis (CM) in dairy cattle. Cows from 14 commercial herds were randomly assigned to two experimental groups, as follows: 1) PCEF: received intramammary treatment (IMM) containing 250 mg of cefoperazone and 4 mg of prednisolone every 48 hours, totaling 2 applications (N = 143) and 2) CEF: treated only with cefoperazone, as previously described (N = 130). Milk samples were collected for each mammary quarter included in the study on the day of detection of the case (D0), and 14 (D14) and 21 (D21) days after D0, to perform microbiological diagnosis and somatic cell count (SCC). The outcomes were microbiological cure, clinical cure, recurrence of CM, risk of new IMI at D14 and D21, SCC at D14 and D21, and cow-level milk production and SCC at the 1st, 2nd, and 3rd monthly tests after CM. A total of 288 CM cases were randomized into PCEF (n = 147) or CEF (n = 141). Clinical cure (PCEF = 81.63% and CEF = 82.27%) and the median (1st - 3rd quartile) time to clinical cure [PCEF = 3.0 (2.5-4.0 days) and CEF = 3.50 (3.0-4.0) days] were not different between the treatments. The risk of clinical cure was 1.86 (95% CI: 1.38-2.51) times higher for mild cases, as compared with moderate cases. Microbiological cure (PCEF = 68.87% and CEF = 54.21%) was not different between the treatments. Cases associated with Gram-negative pathogens were 5.40 (95% CI: 1.84-15.91) times more likely to cure than those associated with Gram-positive pathogens. Recurrence of CM (PCEF = 26.67% and CEF = 21.93%) and the median time to recurrence (PCEF = 63.5 and CEF = 65 days) were not different between the treatments. For culture-negative quarters at D0, the incidence of new IMI at D14 (PCEF = 18.75% and CEF = 34.78%) and D21 (PCEF = 28.13% and CEF = 39.13%) were not different between the treatments. Quarter milk SCC was numerically higher in CEF than in PCEF at D14 and D21, although the differences were not statistically xiii significant. Likewise, no significant differences were found between cow-level SCC or milk production at the 1st, 2nd, and 3rd monthly DHI test after CM. The results of this study indicate that intramammary treatment of natural CM cases with PCEF was not superior to treatment with CEF, based on the risk of clinical and microbiological cure, CM recurrence, risk of new IMI, milk production, and SCC.
The objective of this study was to evaluate the efficacy of a combination of cefoperazone and prednisolone for treatment of natural cases of clinical mastitis (CM) in dairy cattle. Cows from 14 commercial herds were randomly assigned to two experimental groups, as follows: 1) PCEF: received intramammary treatment (IMM) containing 250 mg of cefoperazone and 4 mg of prednisolone every 48 hours, totaling 2 applications (N = 143) and 2) CEF: treated only with cefoperazone, as previously described (N = 130). Milk samples were collected for each mammary quarter included in the study on the day of detection of the case (D0), and 14 (D14) and 21 (D21) days after D0, to perform microbiological diagnosis and somatic cell count (SCC). The outcomes were microbiological cure, clinical cure, recurrence of CM, risk of new IMI at D14 and D21, SCC at D14 and D21, and cow-level milk production and SCC at the 1st, 2nd, and 3rd monthly tests after CM. A total of 288 CM cases were randomized into PCEF (n = 147) or CEF (n = 141). Clinical cure (PCEF = 81.63% and CEF = 82.27%) and the median (1st - 3rd quartile) time to clinical cure [PCEF = 3.0 (2.5-4.0 days) and CEF = 3.50 (3.0-4.0) days] were not different between the treatments. The risk of clinical cure was 1.86 (95% CI: 1.38-2.51) times higher for mild cases, as compared with moderate cases. Microbiological cure (PCEF = 68.87% and CEF = 54.21%) was not different between the treatments. Cases associated with Gram-negative pathogens were 5.40 (95% CI: 1.84-15.91) times more likely to cure than those associated with Gram-positive pathogens. Recurrence of CM (PCEF = 26.67% and CEF = 21.93%) and the median time to recurrence (PCEF = 63.5 and CEF = 65 days) were not different between the treatments. For culture-negative quarters at D0, the incidence of new IMI at D14 (PCEF = 18.75% and CEF = 34.78%) and D21 (PCEF = 28.13% and CEF = 39.13%) were not different between the treatments. Quarter milk SCC was numerically higher in CEF than in PCEF at D14 and D21, although the differences were not statistically xiii significant. Likewise, no significant differences were found between cow-level SCC or milk production at the 1st, 2nd, and 3rd monthly DHI test after CM. The results of this study indicate that intramammary treatment of natural CM cases with PCEF was not superior to treatment with CEF, based on the risk of clinical and microbiological cure, CM recurrence, risk of new IMI, milk production, and SCC.
Descrição
Palavras-chave
Mastite clínica, Vacas leiteiras, Prednisolona, Glicocorticóides, Cefoperazona, Clinical mastitis, Dairy cows, Prednisolone, , Glucocorticoids, Cefoperazone